Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 27, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
In episode 6 of this series, Clyde E. Markowitz, MD, gives a review of data from the ACTRIMS 2020 meeting in light of 6-year follow-up data with ocrelizumab therapy.
Gregory T. Mayes, president and CEO, Engage Therapeutics, and Mark Theeuwes, executive VP and COO, discuss their investigational Staccato alprazolam product in the abortive treatment of seizures.
Kaleb H. Yohay, MD, provides insight on plexiform neurofibromas as they relate to neurofibromatosis type 1 and discusses tumor inoperability.
Data from the DELOS and SYROS studies of idebenone suggest that the investigational DMD therapy has a treatment effect maintained for up to 6 years, which can reduce hospitalizations, bronchopulmonary adverse events, and systemic antibiotic use.
In addition to no-charge testing, patients may have access to the Detect Muscular Dystrophy program, a counseling program designed to aid health decisions and follow-up care.